Bayer's Glyphosate Settlement Calendar Slips Again, Even as the Operating Engine Shows New Life
Published on 08/16/2026 at 13:04 | Redaktion boerse-global.de
The road to closure in Bayer's long-running Roundup litigation just got longer — and the detour runs straight through a landmark Supreme Court ruling. A hearing originally scheduled for August 19 to secure final approval of the $7.25 billion class settlement has been pushed to September 14, with the St. Louis court citing the need to review opt-out requests from individual plaintiffs.
The postponement traces back to the high court's decision in the Durnell case, which prompted Monsanto and plaintiffs' attorneys to jointly ask for a reassessment of how opt-out declarations are validated. The stakes are considerable: the more claimants who exit the class settlement to pursue individual lawsuits, the murkier Bayer's attempt to price its glyphosate liabilities once and for all becomes. For investors, that means the legal overhang that has weighed on the share price for years stays in play for at least another month.
A Quarter That Beat the Consensus
The legal calendar may be slipping, but the operational story is gaining traction. Bayer's second-quarter numbers, released last Thursday, showed revenue of €10.87 billion, up 1.2 percent year over year, while adjusted EBITDA came in at €2.14 billion — comfortably ahead of the €1.94 billion average analyst forecast.
Crop Science, the agricultural division at the heart of the glyphosate saga, delivered the standout performance. Segment operating profit jumped nearly 30 percent to €902 million, buoyed by firmer glyphosate pricing and the EPA's reapproval of dicamba herbicides. The secondary reporting on the quarter adds further texture: adjusted EBITDA for the division rose 30.2 percent, supported by cost reductions, a 12.6 percent uptick in glyphosate-containing herbicide sales, and a 16.9 percent gain in soybean seed revenue.
Management reaffirmed its full-year 2026 guidance, calling for adjusted EBITDA between €9.6 billion and €10.1 billion and core earnings per share of €4.30 to €4.90.
Handling hazardous substances comes with serious compliance duties — and getting the paperwork wrong can prove costly. A free COSHH toolkit gives you 43 ready-to-use templates, checklists and toolbox talks to meet your legal obligations for assessing dangerous substances. Download the free COSHH Toolkit
Analysts Move in Lockstep — Almost
The earnings beat triggered a wave of target-price revisions across the Street within days. Goldman Sachs kicked things off on August 4, with analyst James Quigley reaffirming a "Buy" rating and lifting the target from €62.50 to €63.50. UBS followed the next day, raising its target from €52 to €62 while keeping a "Buy" stance. The DZ Bank chimed in with an increase to €60 from €54, maintaining a "Kaufen" rating. JPMorgan, for its part, stuck with "Overweight" and a €50 target, citing strong results.
The share price, however, has not fully mirrored the analyst enthusiasm. The stock closed Friday at €47.90, down 4.0 percent on the week. That leaves it roughly 5.2 percent above its 50-day moving average of €45.51 but 11 percent below the 52-week high of €53.86 touched in early July. Over twelve months, the picture is far rosier: the shares are still up about 80 percent, reflecting how far the market has already repriced the improving legal and balance-sheet outlook.
Debt Relief and the September Verdict
On the liability side, there is tangible progress beyond the courtroom. Bayer now projects net financial debt of €29 billion to €30 billion, a meaningful improvement from the previously communicated €32 billion to €33 billion range. The company attributes the revision to the already-agreed transaction with funds managed by Apollo.
When compliance obligations pile up, having the right documentation in place makes all the difference. A free Health & Safety toolkit provides ready-to-use risk assessments and checklists covering key UK regulations like COSHH and PUWER — trusted by over 37,000 British businesses. Get the free Health & Safety Toolkit
Technical indicators suggest the stock is neither overbought nor oversold, with an RSI of 51.3 and annualized volatility of 23 percent. That neutrality may not last long. The September 14 hearing is shaping up as the next genuine inflection point — not just for the settlement's final approval, but for whether the Durnell ruling forces a reworking of the opt-out framework that could alter the ultimate cost of the deal. Until that question is answered, the market's patience — and Bayer's share price — will likely remain hostage to the calendar.
